Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA1 | P00915 | 5/20 | 0.40 |
| ▸ | CA2 | P00918 | 5/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7692290 | 0.81 | KEAP1 (0.38) | MEN1KMT2A | |
| SCHEMBL3663531 | 0.74 | MAOA (0.41) | CYP3A4TDP1CSNK2A2CSNK2A1CA12 | |
| SCHEMBL25122892 | 0.74 | CYP3A4 (0.56) | CYP3A4TDP1CSNK2A2CSNK2A1CA12 | |
| SCHEMBL6699717 | 0.73 | CHRNB2 (0.41) | KMT2A | |
| SCHEMBL4597060 | 0.73 | F2 (0.36) | — | |
| SCHEMBL6955341 | 0.72 | MAOA (0.46) | CYP3A4TDP1CSNK2A2CSNK2A1CA12 | |
| SCHEMBL6953013 | 0.72 | MAOA (0.46) | CYP3A4TDP1CSNK2A2CSNK2A1CA12 | |
| SCHEMBL4700870 | 0.72 | TDP1 (0.53) | CYP3A4TDP1CSNK2A2CSNK2A1CA12 | |
| SCHEMBL25122811 | 0.72 | CYP3A4 (0.54) | CYP3A4TDP1CSNK2A2CSNK2A1CA12 | |
| SCHEMBL7262254 | 0.72 | CYP3A4 (0.44) | CYP3A4TDP1CSNK2A2CSNK2A1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642215-B2 | Using cyanoguanidine compound; anticancer agents | LEO PHARMA A/S (DK) | 2003-11-04 | — | — | US | claimed |
| US-20030004192-A1 | Method of modulating NF-kB activity | LEO PHARMA A/S (DK) | 2003-01-02 | — | — | US | claimed |
| US-6346520-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS; PSORIASIS | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004192-A1 | Method of modulating NF-kB activity | IKBKB, NFKBIA, NFKB2 | CYP3A4 3181/4885TDP1 1868/4885CSNK2A2 227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.